Medline shares extended a recent downturn in pre-market trade, slipping roughly 4.4% to $36.06 as investors reacted to the company’s Q1 2026 financial disclosure. The company reported robust top-line expansion but sharply weaker profit metrics, setting off concerns about the near-term earnings trajectory.
On the revenue front, Medline posted first-quarter net sales of $7.4 billion, an increase of 10.7% compared with the prior year. Despite that top-line gain, net income dropped 25.8% to $239 million. Management attributed the decline primarily to a rise in cost of goods sold resulting from tariffs, higher operating expenses incurred to support growth from new customers, and a bonus expense related to the company’s IPO.
Adjusted EBITDA also contracted, falling 10.6% to $776 million. Company disclosures identified tariff costs and investments to win and onboard new customers as the principal headwinds to adjusted profitability for the quarter.
Costs of goods sold rose 14.3% year-over-year, outpacing revenue growth and compressing gross margin to 25.0% from 27.5% in Q1 2025. Management explicitly singled out the impact of tariffs as a key driver of the margin compression in the quarter.
Investor sentiment was further influenced by a string of analyst price-target adjustments in the wake of the results. Deutsche Bank reduced its target to $42 from $48 while retaining a Hold rating. Bernstein trimmed its target to $54 from $56. Citi analyst Patrick Donnelly lowered his price target to $55 from $60, maintaining a Buy rating but dialing back estimates after the quarterly release.
Supply-side selling has also weighed on the share price. Company insiders conducted 28 transactions over the past six months, with 24 of those being sales. In addition, entities affiliated with Carlyle sold more than 45 million shares in transactions estimated at roughly $1.6 billion, contributing material institutional supply into the market.
Research commentary has sought to put the share price moves in context. Baird, in a note dated May 18, 2026, addressed recent declines and investor inquiries. The firm highlighted recent contract wins and updates from Medline on growth, efficiency programs and next-generation investments. Baird said the share price contraction has prompted new investor inquiries and some fresh interest in the stock. The firm characterized the main drivers of the recent price compression as largely exogenous and uncontrollable and described those pressures as transitory in nature, labeling them "good problems" tied to growth and investment rather than core operational failures. Baird emphasized that its note was explanatory rather than prescriptive.
Market commentary following the May 6 results has emphasized several overlapping pressures keeping the stock under strain: a notable post-earnings margin disappointment, a cascade of analyst price-target reductions, heavy institutional share sales by private equity sponsors and a weak broader market. Those factors have left MDLN trading closer to its 52-week low of $34.89 and further from its 52-week high of $50.88.
Investors appear to be awaiting clearer signs that tariff-related headwinds are abating and that profitability can stabilize or recover before recommitting capital to the shares. Until such evidence emerges, the combination of margin compression, outsized share sales and recalibrated analyst expectations is likely to keep the stock under pressure.
Contextual note: The financial and market details reported above reflect company disclosures and analyst commentary tied to Medline’s Q1 2026 results and subsequent market activity.